Lantern Pharma (LTRN) Tops Q4 EPS by 16c

Lantern Pharma (NASDAQ: LTRN) reported Q4 EPS of ($0.31), $0.16 better than the analyst estimate of ($0.47).

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Jefferies upgrades Shopify to Buy on AI commerce tailwinds, sees 30% upside
• Light & Wonder to report Q2 results Aug. 4, reaffirms FY26 outlook
• JPMorgan Starts Shinsegae Inc (004170:KS) at Overweight